Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
Chen Tan, Ai‐ris Y. Collier, Jingyou Yu, et al.
JAMA Network Open (2022) Vol. 5, Iss. 8, pp. e2226335-e2226335
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Covid-19 Vaccines — Immunity, Variants, Boosters
Dan H. Barouch
New England Journal of Medicine (2022) Vol. 387, Iss. 11, pp. 1011-1020
Open Access | Times Cited: 378
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
Fangxin Zhao, Xiaodong Zai, Zhiling Zhang, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 56
Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination
Lily E. Adams, Sarah R. Leist, Kenneth H. Dinnon, et al.
Cell Reports (2023) Vol. 42, Iss. 4, pp. 112326-112326
Open Access | Times Cited: 35
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
Xinxue Liu, Alasdair Munro, Annie Wright, et al.
Journal of Infection (2023) Vol. 87, Iss. 1, pp. 18-26
Open Access | Times Cited: 20
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e074325-e074325
Open Access | Times Cited: 20
SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia
Rita M. Meganck, Caitlin E. Edwards, Michael L. Mallory, et al.
Cell Reports (2024) Vol. 43, Iss. 4, pp. 114076-114076
Open Access | Times Cited: 6
Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine
Zhifei Chen, Fangqin Xie, Hairong Zhang, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access
Mechanistic models of humoral kinetics following COVID-19 vaccination
Daniel Stocks, Amy Thomas, Adam Finn, et al.
Journal of The Royal Society Interface (2025) Vol. 22, Iss. 222
Open Access
Vaccination Strategies: Mixing Paths Versus Matching Tracks
Achilleas Livieratos, Charalambos Gogos, Ιάσων Θωμάς, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 308-308
Open Access
Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study
Wooho Sim, Hyunhye Kang, Jin Jung, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain
Tomohiro Takano, Takashi Sato, Ryutaro Kotaki, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population
Marta C Cruz Cisneros, Elizabeth J. Anderson, Brea K. Hampton, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 103-103
Open Access | Times Cited: 4
Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients
Elizabeth A. Thompson, Wabathi Ngecu, Laila Stoddart, et al.
JCI Insight (2023) Vol. 8, Iss. 10
Open Access | Times Cited: 10
The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
Cristina Borralleras, Javier Castrodeza, Pilar Arrazola, et al.
Revista Española de Quimioterapia (2023) Vol. 36, Iss. 5, pp. 507-515
Open Access | Times Cited: 10
A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov
Shenyu Wang, Wenqing Liu, Yuqing Li, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 704-713
Open Access | Times Cited: 10
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing
Puja Jaishwal, Kisalay Jha, Satarudra Prakash Singh
International Journal of Biological Macromolecules (2024) Vol. 277, pp. 134012-134012
Closed Access | Times Cited: 3
Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Soledad González, Santiago Olszevicki, Alejandra Gaiano, et al.
The Lancet Regional Health - Americas (2023) Vol. 27, pp. 100607-100607
Open Access | Times Cited: 8
Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination
Malika Aïd, Kathryn E. Stephenson, Ai‐ris Y. Collier, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial
Sant Muangnoicharoen, Rakpong Wiangcharoen, Saranath Lawpoolsri, et al.
Vaccine (2024) Vol. 42, Iss. 19, pp. 3999-4010
Open Access | Times Cited: 2
Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran
Hamidreza Jamaati, Saeed Karimi, Fariba Ghorbani, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Closed Access | Times Cited: 7
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial
Stefania Capone, Francesco Maria Fusco, Stefano Milleri, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 6, pp. 101084-101084
Open Access | Times Cited: 7
Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
Geon Young Ko, Ji Hyun Lee, Hyunjoo Bae, et al.
Vaccines (2023) Vol. 11, Iss. 10, pp. 1613-1613
Open Access | Times Cited: 7
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 9, pp. 1253-1262
Open Access | Times Cited: 6
Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers
Houda Amellal, Najlaa Assaid, Khadija Akarid, et al.
Vaccine X (2023) Vol. 14, pp. 100288-100288
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top